Vonoprazan-based Therapy Versus Standard Regimen for Helicobacter Pylori Infection Management

Appropriately, half of the global population is infected with H. pylori, and it is now recognized that it causes at least 95% of all gastric cancers. Currently, the main challenge in the field of H. pylori infection is the rapidly increasing antibiotic resistance worldwide, which is causing a decline in the effectiveness of currently available eradication regimens.The aim of the study is to assess the safety and efficacy of different H. pylori vonoprazan-based regimens compared to the commonly used standard triple therapy composed of Clarithromycin, Amoxicillin, and Proton pump inhibitor to eradicate H. pylori infection in treatment-naive patients through the determination of each regimen eradication rate and reported safety profile

Inclusion Criteria:Patients with positive stool antigen test result for H. pyloriPatients recently diagnosed with H. pylori infection and did not receive any treatmentExclusion Criteria:Patients sensitive to any of the regimens' componentsPatients who had received a previous eradication therapy and still show positive test resultsRecent use of antimicrobial agents, proton pump inhibitors, and H2 receptor blockers within 1 monthPatients with gastric malignancy or who underwent previous gastric surgeryPregnancy and lactationPatients with major concomitant diseases, including psychic disorders